- Home
- / Profound Medical
Profound Medical
Stock Price
$10.3
2024-10-29
Market Capitalization
$251.9 M
2024-10-29
Revenue
$16.1 M
FY, 2025
Profound Medical Summary
Company Summary
- Overview
- Profound Medical is a company focused on the development of therapeutic technology for the treatment of prostate cancer. It offers TULSA-PRO, a non-invasive, image-guided treatment system that uses ultrasound and magnetic resonance imaging to target diseased tissue.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Mississauga, CA | view all locations
- Website
- https://profoundmedical.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Steve Forte, Director
Michael Mydra, VP, Head of Global Market Access
Brian Ellacott, Director
LocationsView all
3 locations detected
Mississauga, ON HQ
Canada
2400 Skymark Ave #6
Vantaa
Finland
Äyritie 4
Hamburg, Hamburg
Germany
9 Kehrwieder
Profound Medical Financials
Summary Financials
- Revenue (Q1, 2026)
- $5.3M
- Gross profit (Q1, 2026)
- $3.9M
- Net income (Q1, 2026)
- ($7.1M)
- Cash (Q1, 2026)
- $50.3M
- EBIT (Q1, 2026)
- ($8.0M)
- Enterprise value
- $209.1M